Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 67

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis63Systemic lupus erythematosus63Psoriatic arthropathy46Myasthenia gravis44Systemic scleroderma40Sjogren's syndrome31Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis16Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+307

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Giant cell tumour of tendon sheath

Not recruiting

Study on the Safety and Effectiveness of ABSK021 for Patients with Tenosynovial Giant Cell Tumor

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ABSK021 hydrochloride hydrate
  • Sponsor:Abbisko Therapeutics Co. Ltd.

Study on the Effectiveness and Safety of Secukinumab for Adults with Moderate to Severe Rotator Cuff Tendinopathy

Not recruiting
Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Lupus nephritis

Not recruiting

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Kezar Life Sciences Inc.

Obesity+2

Not recruiting

Study of Retatrutide (LY3437943) for Patients with Obesity or Overweight and Knee Osteoarthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Facioscapulohumeral muscular dystrophy

Not recruiting

Study on the Effectiveness and Safety of Satralizumab for Patients with Type 1 Facioscapulohumeral Muscular Dystrophy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Satralizumab
  • Sponsor:Centre Hospitalier Universitaire De Nice

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Afimetoran for Patients with Active Lupus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Afimetoran Besilate Dihydrate

Osteochondrodysplasia+1

Not recruiting

Study on the Safety and Effects of SAR442501 for Children with Achondroplasia

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cutaneous lupus erythematosus

Not recruiting

Study of GS-5718 for Patients with Cutaneous Lupus Erythematosus (CLE)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:GS-5718-03
  • Sponsor:Gilead Sciences Inc.

Systemic lupus erythematosus+1

Not recruiting

Study of PF-06823859 for Adults with Active Cutaneous or Systemic Lupus Erythematosus with Skin Symptoms

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IGG1K monoclonal antibody against interferon beta
  • Sponsor:Pfizer Inc.

Femur fracture+1

Not recruiting

Study on Methadone and Placebo for Pain Relief in Elderly Patients with Hip Fractures

Registered drug
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Sodium Chloride
  • Sponsor:Sygehus Soenderjylland Soenderborg

Osteogenesis imperfecta

Not recruiting

Study on the Effects of Romosozumab and Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Calcium
  • Sponsor:Amgen Inc.

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate26 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.